COSTS OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) IN COLOMBIA

被引：0
|
作者：
Lasalvia, P. [1 ]
Gil, Rojas Y. [1 ]
Arciniegas Moreno, K. [2 ]
Saturnino, Ltm [2 ]
机构：
[1] CUN, NeuroEconomix, Bogota, Colombia
[2] Astellas, Bogota, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA131
引用
下载
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab and decitabine for relapsed and refractory acute myeloid leukemia (PD-AML)
    Lai, Catherine
    Karolyn, Oetjen
    Lindblad, Katherine
    Destefano, Christin
    Goswami, Meghali
    Wong, Hong Yuen
    Intrater, Therese
    Draper, Debbie
    Dillon, Laura
    Hourigan, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] Gemtuzumab Ozogamicin Containing Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Children
    Liu, Anthony Pak-Yin
    Leung, Alex Wing-Kwan
    Cheuk, Daniel Ka-Leung
    Lee, Vincent
    Ha, Shau-Yin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (02) : 163 - 168
  • [3] Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US
    Aly, Abdalla
    Bapat, Bela
    Ray, Saurabh
    Chen, Zhiyong
    Botteman, Marc
    BLOOD, 2017, 130
  • [4] Treatment for Relapsed/Refractory Acute Myeloid Leukemia
    Thol, Felicitas
    Heuser, Michael
    HEMASPHERE, 2021, 5 (06): : E572
  • [5] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Bose, Prithviraj
    Vachhani, Pankit
    Cortes, Jorge E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (03)
  • [6] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Prithviraj Bose
    Pankit Vachhani
    Jorge E. Cortes
    Current Treatment Options in Oncology, 2017, 18
  • [7] OUTCOMES OF SALVAGE CHEMOTHERAPY REGIMENS IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Tak, Himangi
    Trivedi, Maharshi
    Joshi, Nitin
    Panchal, Harsha
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S553 - S553
  • [8] Time-sequential chemotherapy as treatment for refractory or relapsed adult acute myeloid leukemia (AML).
    Martino, R
    Altés, A
    Guárdia, R
    Sureda, A
    Brunet, S
    Briones, J
    Sierra, J
    BLOOD, 1998, 92 (10) : 217B - 217B
  • [9] Patterns of failure for refractory or relapsed acute myeloid leukemia (AML) displaying a normal karyotype.
    Thomas, X
    Chelghoum, Y
    Le, QH
    Revesz, D
    Elhamri, M
    Troncy, J
    Michallet, M
    BLOOD, 2003, 102 (11) : 248B - 248B
  • [10] Outcome of Refractory and Relapsed Patients with Acute Myeloid Leukemia
    Niederwieser, Dietger
    Krahl, Rainer
    Kahle, Christoph
    Scholl, Sebastian
    Wolf, Hans-Heinrich
    Cross, Michael
    Hegenbart, Ute
    Peter, Norma
    Niederwieser, Christian
    Florschuetz, Axel
    Reifenrath, Kolja F. B.
    Zojer, Niklas
    Junghanss, Christian
    Sayer, Herbert
    Schmidt, Volker
    Maschmeyer, Georg
    Hochhaus, Andreas
    Fischer, Thomas
    Al-Ali, Haifa Kathrin
    Heinicke, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 106 - 106
12345